ArticleInternational journal of clinical and experimental pathology2015
Expression of PHF20 protein contributes to good prognosis of NSCLC and is associated with Bax expression.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma.Cell death & disease · 2026Article
- Machine learning and gene network integration reveal prognostic subnetworks and biomarkers in pancreatic cancer.Computational and structural biotechnology journal · 2025Article
- Unveiling the link between arsenic toxicity and diabetes: an in silico exploration into the role of transcription factors.Toxicological research · 2024Article
- PHF20 is a Novel Prognostic Biomarker and Correlated with Immune Status in Breast Cancer.Biochemical genetics · 2023Article
- N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.Clinical and translational medicine · 2022Article
- PHF20 inhibition promotes apoptosis and cisplatin chemosensitivity via the OCT4‑p‑STAT3‑MCL1 signaling pathway in hypopharyngeal squamous cell carcinoma.International journal of oncology · 2021Article
- The non-specific lethal (NSL) complex at the crossroads of transcriptional control and cellular homeostasis.EMBO reports · 2019Review
- Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line.Cancer cell international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies demonstrate that plant homeodomain finger protein 20 (PHF20), which was initially described as an immunogenic antigen in glioblastoma, is a putative transcriptional factor, and exhibits tumor suppressor activity. However, little is known about its expression and clinical significance in lung cancer.
methodsWe investigated the expression of PHF20 in 142 cases of NSCLC tissue and 30 cases of normal lung tissue by immunohistochemical staining and downregulated PHF20 expression in SPC cell.
resultsPHF20 expression was significantly higher in normal lung tissues than that in NSCLC tissues. The expression of PHF20 in NSCLC was significantly correlated with histological grade, p-TNM stage and lymph node metastasis. Moreover, the loss of PHF20 expression was associated with short overall survival. We also found that the expression of PHF20 was associated with Bax expression. Additionally, PHF20 markedly inhibited cell proliferation and invasion.
conclusionsPHF20 may play an important role in NSCLC, and may serve as a potential therapeutic target of NSCLC.
Indexed as
Identifiers
26722404PMC4680349W2412144781What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.